|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Respondr® TNF
Test Code18555
CPT Codes
81599<br>Restricted Client Code
Preferred Specimen
3 mL whole blood collected in an EDTA (lavender-top) tube
Patient Preparation
IBD patients ≥35 kg
Respondr TNF is a precision-medicine test that requires patient weight, in kg, at the time of sample collection for testing to occur. Failure to provide the required information at the time of ordering, will result in reporting delays or cancellation.
Minimum Volume
3 mL
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 10 days
Refrigerated: 30 days
Frozen: Unacceptable
Refrigerated: 30 days
Frozen: Unacceptable
Methodology
Genotyping • Quantitative Polymerase Chain Reaction • SNP Targeted Sequencing
Setup Schedule
Set up: Varies; Report available: 5 business days from data of receipt
Reference Range
| Pre-Therapy Clearance | <0.326 L/day |
| HLA DQA1*05 | See Laboratory Report |
| Albumin | 3.7-5.1 g/dL |
Clinical Significance
Respondr® TNF is a test that indicates the likelihood of response to infliximab, adalimumab, or their biosimilars, prior to initiation of therapy. The test provides objective evidence to help guide therapeutic selection by stratifying patients based on how their unique pharmacokinetic and genetic profile influences their ability to acheive and sustain a therapeutic response to anti-TNF therapy. The test also indentifies those who may benefit from more active therapeutic management.
Pre-therapy drug clearance, a pharmacokinetic patient characteristic, is derived via a populaton pharamcokinetic model-based formula that combines patient-specific variables and laboratory results. HLA-DQA1*05 risk variant status is determined by a single nucleotide polymorphism (SNP) rs2097432 quantitative PCR genotyping assay.
Pre-therapy drug clearance, a pharmacokinetic patient characteristic, is derived via a populaton pharamcokinetic model-based formula that combines patient-specific variables and laboratory results. HLA-DQA1*05 risk variant status is determined by a single nucleotide polymorphism (SNP) rs2097432 quantitative PCR genotyping assay.
